Simon Glairy is a titan in the insurance world, specifically known for his surgical precision in identifying systemic risks within the insurtech and risk assessment landscapes. With years spent dissecting complex fraud patterns and advising carriers on how to leverage advanced analytics to protect their bottom line, Glairy offers a unique perspective on the evolving threats facing the industry today. In this discussion, we explore the intricate mechanics of organized insurance fraud, the legal vulnerabilities in specific jurisdictions like New York, and the high-stakes federal battle between carriers and sophisticated schemes involving legal and medical professionals.
This conversation delves into the structural challenges posed by the “duty to defend” rule, which forces immediate insurer spending on potentially fraudulent claims. We also examine the disturbing “assembly line” approach to medical escalation, where minor injuries like knee abrasions are transformed into six-figure spinal surgeries through a coordinated network of runners, clinics, and surgeons. Finally, we look at the systemic barriers, such as HIPAA and the secrecy of litigation funding, that allow these schemes to flourish until they are challenged by powerful tools like the federal RICO statute.
How does the legal requirement to defend a lawsuit immediately upon filing, regardless of its validity, create a structural vulnerability for insurance carriers?
The duty to defend is a double-edged sword that, in jurisdictions like New York, can be weaponized against carriers the moment a summons is served. Because the law mandates that insurers provide a defense even for allegations that are completely groundless, false, or fraudulent, it creates an immediate financial drain on carriers like Wesco and Technology Insurance Company. These companies are forced to deploy high-cost resources—including specialized counsel, private investigators, and medical experts—before they even have the chance to test the veracity of the underlying injury. This “instant cost” feature essentially grants bad actors a head start, as the insurer is already playing a defensive, high-stakes game of catch-up while the clock is ticking on a claim that may have been manufactured from thin air.
Could you explain the operational “assembly line” described in these types of fraud allegations and how it successfully inflates the value of a claim?
The alleged “Fraud Scheme” outlined in the June 2, 2026, federal complaint functions like a well-oiled machine, where each stage is designed to add a layer of perceived legitimacy to a fake claim. It begins with “runners” who identify and recruit potential claimants, often from routine sidewalk slips involving small businesses, and moves them into a “standardized referral pipeline.” From there, gatekeeper clinics and radiology providers collaborate to manufacture reports that support the need for invasive surgical procedures, regardless of the patient’s actual medical necessity. We see a stark example in the case of a 26-year-old claimant who arrived at a hospital with nothing more than a “right knee abrasion” and specifically denied neck pain, yet somehow ended up with a two-level cervical spine fusion. The sheer audacity of billing $182,111.02 for surgery and implants on such a minor injury shows how these “templated medical records” are used to drive up costs for the carrier.
What is the impact of “surgical escalation” on an insurer’s decision-making process when it comes to settling claims that might otherwise be seen as low-value?
Surgical escalation is the ultimate leverage point because it transforms a low-risk slip-and-fall into a potential “catastrophic verdict” that keeps claims adjusters up at night. Once a surgeon performs an invasive procedure, like the knowingly unnecessary ankle arthroscopy or spine fusion mentioned in the filing, the settlement value of the case skyrockets to protect against excess judgments. For instance, one case that began as a routine matter was settled for a staggering $1,250,000.00 on March 22, 2024, with a full $1,000,000.00 of that charged directly to Associated Industries. Another claim settled for $865,000 just weeks prior, proving that the manufactured pressure of an invasive surgery record often forces insurers to settle claims that would otherwise have little or no value.
In your experience, how do protections like HIPAA and attorney-client privilege inadvertently serve as a shield for those attempting to orchestrate large-scale insurance fraud?
One of the most frustrating aspects for claims professionals is that the very laws designed to protect consumer privacy are frequently the same ones that hide the tracks of a coordinated fraud scheme. By shielding medical records and the inner workings of “bribery and kickback” arrangements, these protections make it nearly impossible for even the most “reputable defense firms” to see the full picture across multiple files. Furthermore, New York’s practice of shielding litigation-financing disclosures means that insurers are often unaware that a case is being bankrolled by third parties who expect a cut of the final payout. This creates a “black box” environment where templated records and unnecessary surgeries can be repeated across dozens of cases without the carrier realizing they are being targeted by a singular, assembly-line operation.
What are the strategic implications of an insurance carrier pursuing a federal RICO suit against medical and legal professionals instead of simply fighting individual claims?
Filing a federal racketeering suit is a massive escalation that shifts the insurer from a defensive posture to an offensive one, signaling that they will no longer tolerate being treated like a corporate ATM. By invoking the RICO statute and citing violations of 18 U.S.C. § 1952, the AmTrust carriers are aiming for much more than just a refund of paid claims; they are seeking treble damages and the recovery of their substantial attorney fees. This strategy targets the entire infrastructure of the alleged scheme, from the podiatrists who allegedly lack proper ankle privileges to the neurosurgeons and the law firm coordinating the filings. It is a high-stakes move intended to dismantle the economic incentive of the “surgical escalation” model by making the legal consequences far more expensive than the potential settlements.
What is your forecast for the future of litigation involving organized insurance fraud schemes and the use of the RICO statute?
I expect to see a significant rise in carriers utilizing federal RICO actions as a primary tool to disrupt the “standardized referral pipelines” that have plagued the liability market for years. As data analytics and AI-driven risk assessment become more sophisticated, insurers will be able to identify patterns of “templated medical records” much earlier in the process, leading to more aggressive pre-emptive filings. The outcome of the AmTrust case, specifically regarding the $216,185.50 in billed medical charges and the massive settlements reaching $1.25 million, will likely serve as a blueprint for other carriers. Ultimately, the industry will push for greater transparency in litigation financing to ensure that the shielding of these arrangements no longer provides a safe harbor for those seeking to manufacture catastrophic verdicts out of thin air.
